371 related articles for article (PubMed ID: 21562253)
21. Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis.
Yasuda M; Uzawa A; Ozawa Y; Kojima Y; Onishi Y; Akamine H; Kuwabara S
Scand J Immunol; 2022 Feb; 95(2):e13122. PubMed ID: 34796975
[TBL] [Abstract][Full Text] [Related]
22. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
[TBL] [Abstract][Full Text] [Related]
23. Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
Barnett C; Bril V; Kapral M; Kulkarni AV; Davis AM
Neurology; 2017 Dec; 89(23):2357-2364. PubMed ID: 29101274
[TBL] [Abstract][Full Text] [Related]
24. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
[TBL] [Abstract][Full Text] [Related]
25. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.
Gajdos P; Tranchant C; Clair B; Bolgert F; Eymard B; Stojkovic T; Attarian S; Chevret S;
Arch Neurol; 2005 Nov; 62(11):1689-93. PubMed ID: 16286541
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study.
Pasnoor M; Bril V; Levine T; Trivedi J; Silvestri NJ; Phadnis M; Katzberg HD; Saperstein DS; Wolfe GI; Herbelin L; Higgs K; Heim AJ; Statland JM; Barohn RJ; Dimachkie MM
Eur J Neurol; 2023 May; 30(5):1417-1424. PubMed ID: 36779862
[TBL] [Abstract][Full Text] [Related]
27. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.
Wolfe GI; Barohn RJ; Foster BM; Jackson CE; Kissel JT; Day JW; Thornton CA; Nations SP; Bryan WW; Amato AA; Freimer ML; Parry GJ;
Muscle Nerve; 2002 Oct; 26(4):549-52. PubMed ID: 12362423
[TBL] [Abstract][Full Text] [Related]
28. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.
Heatwole C; Johnson N; Holloway R; Noyes K
J Clin Neuromuscul Dis; 2011 Dec; 13(2):85-94. PubMed ID: 22361692
[TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes.
Alabdali M; Barnett C; Katzberg H; Breiner A; Bril V
Expert Rev Clin Immunol; 2014 Dec; 10(12):1659-65. PubMed ID: 25331319
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of therapeutic options used for myasthenia gravis.
Mandawat A; Kaminski HJ; Cutter G; Katirji B; Alshekhlee A
Ann Neurol; 2010 Dec; 68(6):797-805. PubMed ID: 21061395
[TBL] [Abstract][Full Text] [Related]
31. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
Illa I
J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
33. Surrogate therapeutic outcome measures in patients with myasthenia gravis.
Zinman L; Baryshnik D; Bril V
Muscle Nerve; 2008 Feb; 37(2):172-6. PubMed ID: 17918748
[TBL] [Abstract][Full Text] [Related]
34. Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.
Eienbröker C; Seitz F; Spengler A; Kurz H; Seipelt M; Sommer N; Oertel WH; Timmesfeld N; Tackenberg B
Muscle Nerve; 2014 Dec; 50(6):999-1004. PubMed ID: 24710856
[TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2006 Apr; (2):CD002277. PubMed ID: 16625559
[TBL] [Abstract][Full Text] [Related]
36. High-dose intravenous immunoglobulin therapy for myasthenia gravis.
Jongen JL; van Doorn PA; van der Meché FG
J Neurol; 1998 Jan; 245(1):26-31. PubMed ID: 9457625
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin treatment in refractory Myasthenia gravis.
Achiron A; Barak Y; Miron S; Sarova-Pinhas I
Muscle Nerve; 2000 Apr; 23(4):551-5. PubMed ID: 10716766
[TBL] [Abstract][Full Text] [Related]
38. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial.
Katzberg HD; Barnett C; Merkies IS; Bril V
Muscle Nerve; 2014 May; 49(5):661-5. PubMed ID: 24810970
[TBL] [Abstract][Full Text] [Related]
39. Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital.
Pittayanon R; Treeprasertsuk S; Phanthumchinda K
J Med Assoc Thai; 2009 Apr; 92(4):478-82. PubMed ID: 19374297
[TBL] [Abstract][Full Text] [Related]
40. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.
Jensen P; Bril V
J Clin Neuromuscul Dis; 2008 Mar; 9(3):352-5. PubMed ID: 18344718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
